Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ann Steward LaCasce, M.D.

Co-Author

This page shows the publications co-authored by Ann LaCasce and Reid Merryman.
Connection Strength

3.261
  1. Novel agents and immune invasion in Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):243-248.
    View in: PubMed
    Score: 0.894
  2. Reply to H.J.A. Adams et al. J Clin Oncol. 2018 Nov 10; 36(32):3274-3275.
    View in: PubMed
    Score: 0.822
  3. Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care. J Clin Oncol. 2018 07 10; 36(20):2009-2011.
    View in: PubMed
    Score: 0.803
  4. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659.
    View in: PubMed
    Score: 0.244
  5. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
    View in: PubMed
    Score: 0.228
  6. A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
    View in: PubMed
    Score: 0.060
  7. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126.
    View in: PubMed
    Score: 0.056
  8. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32.
    View in: PubMed
    Score: 0.056
  9. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29.
    View in: PubMed
    Score: 0.053
  10. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.